Belvedere Trading
BCTX

Belvedere Trading’s Briacell Therapeutics BCTX Stock Holding History

Belvedere Trading’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5
Closed -$3.06K – 945
2022
Q4 		$3.06K Buy
+5
New +$4.24K ﹤0.01% 1018

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Belvedere Trading's BCTX Position: Q3 2023 in Review

Belvedere Trading sold out of Briacell Therapeutics (BCTX) in Q3 2023, closing a stake of 25 shares — an estimated $30.7K sold.

Belvedere Trading first reported a position in BCTX in Q3 2021 and held it in 2 quarters. The position peaked at $107K in Q3 2021. 18 funds tracked by Wall St. Rank hold BCTX as of Q3 2023.

  • Belvedere Trading reported no remaining Briacell Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Belvedere Trading sold 25 Briacell Therapeutics shares in Q3 2023, an estimated $30.7K.
  • Belvedere Trading first reported a position in Briacell Therapeutics in Q3 2021 and held it in 2 quarters.
  • Belvedere Trading's Briacell Therapeutics position peaked at $107K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.